237 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
26 Mar 14
Discovery Labs Announces New Appointments to Management Team
12:00am
with ViroPharma Incorporated (recently acquired by Shire), most recently serving as Vice President, Corporate Communications, with responsibility … . (acquired by AstraZeneca in 2007) in various scientific and investor relations roles of increasing responsibility. While at MedImmune, he focused primarily
8-K
WINT
Windtree Therapeutics Inc
25 Aug 10
Departure of Directors or Certain Officers
12:00am
and will be responsible for the strategic and organizational development of the Company while retaining overall responsibility for the Company’s financial operations … . Thomas F. Miller, Ph.D., MBA, has assumed the position of Chief Operating Officer and will have responsibility for product development, regulatory
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
25 Aug 10
Departure of Directors or Certain Officers
12:00am
Operating Officer and will have responsibility for product development (including preclinical and clinical operations), regulatory affairs, and corporate … , Commercial and Corporate Development.
Charles F. Katzer has been appointed Chief Technical Officer and will have responsibility for manufacturing
8-K
WINT
Windtree Therapeutics Inc
28 Aug 23
Departure of Directors or Certain Officers
4:15pm
and served in various finance roles of increasing responsibility, most recently as Executive Director, Corporate Controller. Previously, Ms. McAndrew held … roles of increasing responsibility at KPMG LLP from January 2008 to October 2013, at which time she served as a Manager in Transaction Services. Ms
8-K
EX-10.1
h0yrgzixfm5 4s
8 Jan 13
Entry into a Material Definitive Agreement
12:00am
S-1/A
EX-10.50
hrpp6oc0jfu9w7
6 May 20
IPO registration (amended)
5:31pm
8-K
EX-10.2
d6bvr79zy t24r
6 Apr 07
Entry into a Material Definitive Agreement
12:00am
S-1/A
EX-4.14
7cod7
6 May 20
IPO registration (amended)
5:31pm
8-K
EX-4.2
jivme7 gg
24 Mar 21
Entry into a Material Definitive Agreement
5:20pm
8-K
EX-4.2
gnx70gmde845q90e2
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K/A
EX-2.5
yk8a9i3lgyg7k
21 Jul 97
Financial statements and exhibits
12:00am
8-K
EX-10.1
7pzplt5a3f3qxl206
19 Dec 01
Other events
12:00am
8-K
EX-10.1
fmu94h rfwtcnm905
12 Dec 05
Entry into a Material Definitive Agreement
12:00am